Proteasome inhibitors suppress the protein expression of mutant p53

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The tumor suppressor p53 is frequently mutated in nearly 50% of human cancers.
• p53's primary negative regulator, HDM2, is an E3 ubiquitin ligase that targets p53 for proteasomal degradation.
• Proteasome inhibitors typically prevent the degradation of cellular proteins, including wild-type p53.

Purpose of the Study:

• To investigate the effect of proteasome inhibitors on mutant p53 protein expression.
• To explore the mechanism underlying proteasome inhibitor-mediated suppression of mutant p53.
• To evaluate the therapeutic potential of proteasome inhibitors in mutant p53-driven cancers.

Main Methods:

• Treatment of cancer cells with established and novel proteasome inhibitors.
• Assessment of mutant p53 protein levels following proteasome inhibitor treatment.
• Investigation of HDM2's role using knockdown experiments.
• Evaluation of arsenic trioxide's proteasome inhibitory activity.

Main Results:

• Proteasome inhibitors suppressed mutant p53 protein expression, contrasting with their effect on wild-type p53.
• Arsenic trioxide demonstrated proteasome inhibitory activity and suppressed mutant p53 levels.
• HDM2 knockdown partially rescued the suppression of mutant p53, indicating HDM2 stabilization contributes to this effect.
• Mutant p53 suppression by proteasome inhibitors appears to be a general phenomenon.

Conclusions:

• Proteasome inhibitors exhibit a unique effect on mutant p53, suppressing its protein expression.
• The stabilization of HDM2 by proteasome inhibitors plays a partial role in mutant p53 suppression.
• These findings provide a strong rationale for utilizing proteasome inhibitors in the treatment of cancers harboring mutant p53.